Pfizer sunitinib

USAN Sunitinib Trade name Sutent Pfizer... 

Sunitinib (7),10 developed by Sugene/Pfizer, was approved in 2006 for the treatment of renal cell carcinoma (RCC). It is a VEGFR kinase inhibitor that slows down the angiogenesis of tumor endothelial cells, which provide nutrients and help tumor growth and metastasis. Sunitinib also blocks KIT, an oncogenic kinase that causes gastrointestinal stromal cell tumors. It was approved as a second-line anti-GSIT therapy for imatinib-resistant patients. 

Sunitinib maleate (1, Sutent, SU11248) was discovered by Sugen, which later became part of Pfizer. It is an orally active drug that exhibits potent anti-angiogenic activity through the inhibition of multiple RTKs. Specifically, 1 inhibits vascular... 

Sutent / Sunitinib e Pfizer GIST, renal cell carcinoma VEGFR, PDGFR, FLT3, KIT 398... 

Dasatinib(BMS), Multiple Sunitinib(Pfizer), Multiple Erlotinib(OSI/Genentech/Roche), EGFR... 

Sunitinib Sutent Pfizer 2006 Multitargeted kinase inhibitor Imatinib-resistent gastrointestinal stromal tumour and advanced renal cell carcinoma 129... 

PDGF receptor p (PDGFRB), and c-kit, a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. As compared with the two drugs on the market, sorafenib (Nexavar) by Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals, Inc. and sunitinib (Sutent) by Pfizer, Inc., cediranib inhibits VEGFR targets with improved potency. It is currently in Phase II/III development for advanced non-small cell lung cancer and advanced colorectal cancer. 

---